Preliminary efficacy and safety of Reishi & Privet Formula on quality of life among non–small cell lung cancer patients undergoing chemotherapy: A randomized placebo-controlled trial Journal Article
| Authors: | Liu, J.; Mao, J. J.; Li, S. Q.; Lin, H. |
| Article Title: | Preliminary efficacy and safety of Reishi & Privet Formula on quality of life among non–small cell lung cancer patients undergoing chemotherapy: A randomized placebo-controlled trial |
| Abstract: | Background: Cancer patients often experience decreased quality of life during chemotherapy. This study aimed to determine the preliminary efficacy and safety of Reishi & Privet Formula (RPF) for maintaining quality of life among patients with non–small cell lung cancer (NSCLC) undergoing chemotherapy. Methods: We conducted a phase II randomized, double-blind, placebo-controlled clinical trial in China. Adults with NSCLC scheduled to receive chemotherapy were randomly assigned (3:1 ratio) to receive oral RPF (3.36 g/day) or placebo daily for 6 weeks. The main outcome was the Functional Assessment of Cancer Therapy–Lung (FACT-L). We evaluated RPF’s safety profile using the Common Terminology Criteria for Adverse Events and assessed changes in outcome measures from baseline to weeks 3 and 6 using a linear mixed effects model. Results: We enrolled 82 participants across 8 cancer centers in China. The median age was 59 years, 56 (68%) had advanced cancer. Compared with the placebo group, the RPF group had nonstatistically significant higher quality of life as measured by the FACT-L total score (P =.086) over 2 cycles of chemotherapy. The RPF group was associated with a nonsignificant better general health (P =.050) and emotional well-being (P =.090) than the placebo group. Adverse events rates did not differ between groups. Conclusions: This study demonstrated preliminary safety and suggests a promising trend in RPF’s effect on maintaining quality of life and emotional well-being among NSCLC patients undergoing chemotherapy. Future adequately powered randomized-controlled trials are needed to verify the efficacy and safety of RPF in cancer patients undergoing chemotherapy. © The Author(s) 2020. |
| Keywords: | chemotherapy; quality of life; traditional chinese medicine; herbs; non–small cell lung cancer; randomized placebo-controlled trial; reishi & privet formula |
| Journal Title: | Integrative Cancer Therapies |
| Volume: | 19 |
| ISSN: | 1534-7354 |
| Publisher: | Sage Publications |
| Date Published: | 2020-01-01 |
| Language: | English |
| DOI: | 10.1177/1534735420944491 |
| PROVIDER: | scopus |
| PUBMED: | 32840126 |
| PMCID: | PMC7450289 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 September 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work